Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Other Non-Current Assets (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Other Non-Current Assets for 13 consecutive years, with $7688.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets changed 0.0% to $7688.0 in Q4 2025 year-over-year; TTM through Oct 2025 was $7688.0, a 0.0% change, with the full-year FY2025 number at $7688.0, changed 0.0% from a year prior.
  • Other Non-Current Assets was $7688.0 for Q4 2025 at PharmaCyte Biotech, roughly flat from $7688.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $2.0 million in Q1 2024 to a low of $7372.0 in Q1 2021.
  • A 5-year average of $107856.2 and a median of $7688.0 in 2021 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: soared 26070.66% in 2024, then tumbled 99.62% in 2025.
  • PharmaCyte Biotech's Other Non-Current Assets stood at $7688.0 in 2021, then changed by 0.0% to $7688.0 in 2022, then changed by 0.0% to $7688.0 in 2023, then changed by 0.0% to $7688.0 in 2024, then changed by 0.0% to $7688.0 in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Other Non-Current Assets are $7688.0 (Q4 2025), $7688.0 (Q3 2025), and $7688.0 (Q2 2025).